Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans.

Lieberman SA, Bukar J, Chen SA, Celniker AC, Compton PG, Cook J, Albu J, Perlman AJ, Hoffman AR

The Journal of clinical endocrinology and metabolism1 Jul 1992Cited by 46 (Europe PMC)

PMID1377706DOI10.1210/jcem.75.1.1377706PepBankPUB-01377706

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanNon-randomized trialPharmacokinetics
In healthy males, total IGF-I increased significantly over 0-24 h after IGF-I on day 1.
In plain wordsIn healthy males, total IGF-I increased after the first dose.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseTotal IGF-I on day 1
Study
n = 12
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Measurements
Total IGF-I
120 micrograms/L
day 1, 0 h (SD 44)
Total IGF-I
166 micrograms/L
day 1, 24 h (SD 51)
P value for Total IGF-I on day 1
0.0002 dimensionless
Total IGF-I at 0 h versus 24 h on day 1
Source sentences
Summary
Total IGF-I increased significantly from 0-24 h after administration on day 1 (mean +/- SD, micrograms/L: 120 +/- 44 to 166 +/- 51, P = 0.0002)
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770601
02HumanNon-randomized trialPharmacokinetics
In healthy males, total IGF-I did not significantly increase from 24 h on day 1 to 0 h on day 5.
In plain wordsIn healthy males, total IGF-I did not significantly increase between the end of the first day and the last dose.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeTotal IGF-I between treatment days
Study
n = 12
Comparator
24 h on day 1
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Measurements
Total IGF-I
166 micrograms/L
24 h on day 1 (SD 51)
Total IGF-I
178 micrograms/L
0 h on day 5 (SD 62)
Source sentences
Summary
but did not increase significantly from 24 h on day 1 to 0 h on day 5 (166 +/- 51 to 178 +/- 62)
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770602
03HumanNon-randomized trialPharmacokinetics
In healthy males, total IGF-I did not significantly increase over 0-24 h on day 5.
In plain wordsIn healthy males, total IGF-I did not significantly increase over the last treatment day.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeTotal IGF-I on day 5
Study
n = 12
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Measurements
Total IGF-I
178 micrograms/L
day 5, 0 h (SD 62)
Total IGF-I
209 micrograms/L
day 5, 24 h (SD 89)
Source sentences
Summary
but did not increase significantly from 24 h on day 1 to 0 h on day 5 (166 +/- 51 to 178 +/- 62) or from 0-24 h on day 5 (178 +/- 62 to 209 +/- 89).
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770603
04HumanNon-randomized trialPharmacokinetics
In healthy males, total IGF-I area under the curve was greater on day 5 than day 1.
In plain wordsIn healthy males, total IGF-I exposure was greater on the last treatment day than the first.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseTotal IGF-I area under curve
Study
n = 12
Comparator
Day 1
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Measurements
Total IGF-I area under the curve
311 min.g/L
day 5 (SD 99)
Total IGF-I area under the curve
249 min.g/L
day 1 (SD 77)
P value for Total IGF-I area under curve
0.0001 dimensionless
Total IGF-I area under the curve on day 5 versus day 1
Source sentences
Summary
The area under the total IGF-I concentration curve was greater on day 5 than day 1 (311 +/- 99 min.g/L vs. 249 +/- 77, P = 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770604
05HumanNon-randomized trialPharmacokinetics
In healthy males, free IGF-I concentrations did not significantly differ between days 1 and 5.
In plain wordsIn healthy males, free IGF-I levels did not differ significantly between the first and last treatment days.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeFree IGF-I concentration
Study
n = 12
Comparator
Day 1
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Source sentences
Summary
There were no significant differences in free IGF-I concentration or pharmacokinetic parameters or in the degree or timing of hypoglycemia between days 1 and 5.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770605
06HumanNon-randomized trialPharmacokinetics
In healthy males, free IGF-I pharmacokinetic parameters did not significantly differ between days 1 and 5.
In plain wordsIn healthy males, free IGF-I processing did not differ significantly between the first and last treatment days.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeFree IGF-I pharmacokinetic parameters
Study
n = 12
Comparator
Day 1
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Source sentences
Summary
There were no significant differences in free IGF-I concentration or pharmacokinetic parameters or in the degree or timing of hypoglycemia between days 1 and 5.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770606
07HumanNon-randomized trialSafety outcome
In healthy males, the degree of hypoglycemia after IGF-I did not significantly differ between days 1 and 5.
In plain wordsIn healthy males, low blood sugar severity did not differ significantly between the first and last IGF-I treatment days.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeHypoglycemia degree
Study
n = 12
Comparator
Day 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Source sentences
Summary
There were no significant differences in free IGF-I concentration or pharmacokinetic parameters or in the degree or timing of hypoglycemia between days 1 and 5.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770607
08HumanNon-randomized trialSafety outcome
In healthy males, hypoglycemia timing after IGF-I did not significantly differ between days 1 and 5.
In plain wordsIn healthy males, low blood sugar timing did not differ significantly between the first and last IGF-I treatment days.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeHypoglycemia timing
Study
n = 12
Comparator
Day 1
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Source sentences
Summary
There were no significant differences in free IGF-I concentration or pharmacokinetic parameters or in the degree or timing of hypoglycemia between days 1 and 5.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770608
09HumanNon-randomized trialEfficacy outcome
IGF-I significantly reduced plasma insulin on day 1 in healthy males.
In plain wordsIGF-I reduced blood insulin on the first treatment day in healthy males.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseInsulin on day 1
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Measurements
Plasma insulin
53 pmol/L
day 1 baseline (SD 11)
Plasma insulin
18 pmol/L
day 1 nadir at 30 min (SD 6)
P value for Insulin on day 1
0.003 dimensionless
Plasma insulin at day 1 baseline versus nadir at 30 min
Source sentences
Summary
Plasma insulin levels decreased significantly following rhIGF-I administration (day 1 baseline: 53 +/- 11 pmol/L, nadir: 18 +/- 6 pmol/L at 30 min, P = 0.003); day 5 baseline: 47 +/- 15 pmol/L, nadir: 16 +/- 8 pmol/L at 30 min, P = 0.0003.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770609
10HumanNon-randomized trialEfficacy outcome
IGF-I significantly reduced plasma insulin on day 5 in healthy males.
In plain wordsIGF-I reduced blood insulin on the last treatment day in healthy males.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseInsulin on day 5
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Measurements
Plasma insulin
47 pmol/L
day 5 baseline (SD 15)
Plasma insulin
16 pmol/L
day 5 nadir at 30 min (SD 8)
P value for Insulin on day 5
0.0003 dimensionless
Plasma insulin at day 5 baseline versus nadir at 30 min
Source sentences
Summary
Plasma insulin levels decreased significantly following rhIGF-I administration (day 1 baseline: 53 +/- 11 pmol/L, nadir: 18 +/- 6 pmol/L at 30 min, P = 0.003); day 5 baseline: 47 +/- 15 pmol/L, nadir: 16 +/- 8 pmol/L at 30 min, P = 0.0003.
2 context sentences(design, population, supporting numbers)
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770610
11HumanNon-randomized trialEfficacy outcome
After IGF-I in healthy males, a transient 30-kilodalton IGFBP band appeared, peaked, and diminished.
In plain wordsIn healthy males, a 30-kilodalton IGF-binding protein band appeared temporarily after IGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseTransient IGFBP band
Study
n = 12
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Measurements
Time to peak of 30-kilodalton band
150 to 210 min
after rhIGF-I administration
Time to diminished band
480 to 600 min
after rhIGF-I administration
Source sentences
Summary
Western ligand blotting revealed the transient appearance of a 30-kilodalton band which migrates in a manner similar to IGFBP-1.
4 context sentences(design, population, supporting numbers)
Summary · context
This band was undetectable at baseline, peaked between 150 and 210 min after rhIGF-I administration, and diminished by 480-600 min.
Summary · context
The response was similar on days 1 and 5.
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770611
12HumanNon-randomized trialEfficacy outcome
In healthy males, the transient IGFBP band response to IGF-I was similar on days 1 and 5.
In plain wordsIn healthy males, the temporary IGF-binding protein response was similar after IGF-I on the first and last treatment days.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeTransient IGFBP band response across days
Study
n = 12
Comparator
Day 1
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Source sentences
Summary
The response was similar on days 1 and 5.
4 context sentences(design, population, supporting numbers)
Summary · context
Western ligand blotting revealed the transient appearance of a 30-kilodalton band which migrates in a manner similar to IGFBP-1.
Summary · context
This band was undetectable at baseline, peaked between 150 and 210 min after rhIGF-I administration, and diminished by 480-600 min.
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770612
13HumanNon-randomized trialEfficacy outcome
IGF-I did not substantially change IGFBP-2 in healthy males.
In plain wordsIGF-I did not substantially change IGFBP-2 in healthy males.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeIGFBP-2
Study
n = 12
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Source sentences
Summary
There were no substantial changes in the serum levels of any other IGFBP.
3 context sentences(design, population, supporting numbers)
Summary · context
IGFBP-2, -3, and -4 were unaffected.
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770613
14HumanNon-randomized trialEfficacy outcome
IGF-I did not substantially change IGFBP-3 in healthy males.
In plain wordsIGF-I did not substantially change IGFBP-3 in healthy males.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeIGFBP-3
Study
n = 12
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Source sentences
Summary
There were no substantial changes in the serum levels of any other IGFBP.
3 context sentences(design, population, supporting numbers)
Summary · context
IGFBP-2, -3, and -4 were unaffected.
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770614
15HumanNon-randomized trialEfficacy outcome
IGF-I did not substantially change IGFBP-4 in healthy males.
In plain wordsIGF-I did not substantially change IGFBP-4 in healthy males.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeIGFBP-4
Study
n = 12
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.03 mg/kg · intravenous bolus · 5 consecutive daysAs given in this study (human).
Source sentences
Summary
There were no substantial changes in the serum levels of any other IGFBP.
3 context sentences(design, population, supporting numbers)
Summary · context
IGFBP-2, -3, and -4 were unaffected.
Summary · context
To examine the effects of repeated administration of recombinant human insulin-like growth factor-I (rhIGF-I) on IGF-I levels, free IGF-I pharmacokinetics, glycemic response, and IGF-binding proteins (IGFBP), we administered rhIGF-I (0.03 mg/kg iv bolus) to 12 healthy males each morning for 5 consecutive days.
Summary · context
Serum was collected over 24 h on days 1 and 5 for measurement of total and free IGF-I, glucose, insulin, and IGFBP.
Report a problemFND-0137770615

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.